CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 160 enrolled
Drug / intervention
Glecaprevir/Pibrentasvirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03235349
NCT03235349Phase 3Completed
CompareCT.gov

An Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-Naïve and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection

AbbVie·interventional·Posted Aug 1, 2017·Updated Nov 21, 2019

In Brief

A Phase 3 clinical trial evaluating Glecaprevir/Pibrentasvir for Hepatitis C Virus (HCV). Completed, enrolled 160 participants across 34 sites in 2 countries.

Detailed Summary

This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with compensated cirrhosis with or without human immunodeficiency virus (HIV) co-infection who are HCV treatment-naïve or treatment-experienced with interferon (IFN) (alpha, beta or pegylated interferon \[pegIFN\]) with or without ribavirin (RBV) OR sofosbuvir with RBV with or without IFN.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C Virus (HCV)
CountriesChina, South Korea
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedAug 1, 2017
Enrollment StartSep 29, 2017
Primary CompletionNov 15, 2018
Study CompletionFeb 25, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.9 years ago

Interventions

Glecaprevir/Pibrentasvirdrug

Coformulated tablet for oral administration